Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom

Meir Medical Center50 enrolled

Overview

Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect instillation. Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year according to consumption data drawn from the Clalit Health Services database, will use the Xal-Ease device for a year. The device is expected to reduce consumption of bottles and result in saving money for both patients and medical care providers.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Glaucoma Hypertension

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with glaucoma or hypertension treated with Xalatan/Xalacom who have consumed more than one bottle per month within a year prior to initiation of the study. Exclusion Criteria: * Patients younger than 18 years, * Patients with severe manual disabilities, * Patients with impaired cognition and mentality.

Outcomes

Primary Outcomes

Consumption of Xalatan/Xalacom bottles per year per patient.

Time frame: 12 months.

Secondary Outcomes

Evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease

Time frame: 12 months

Characterizing the optimal conditions for proper usage of the Xal-Ease device